Biohaven acquires Priority Review Voucher

Biohaven Pharmaceutical Holding Company has purchased an FDA Priority Review Voucher to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019 … more

Biohaven is betting hundreds of millions it can hustle ahead of rivals in a blockbuster race. A quick M&A deal could pay off substantially, says Endpoints News … more